Herbert Yeargan Center for Global Health, Duke University Medical Center, Durham, NC
Laura W. Musselwhite , Catherine M. Thomas , David H. Abbott , Elizabeth R. Hauser , Laura K. Wagner , Sara F. Morris , David G. Weiss , David A. Lieberman , Dawn T. Provenzale
Background: Knowledge of risk factors for interval colorectal neoplasia could inform screening strategies in asymptomatic individuals. Few studies have evaluated risk factors for advanced neoplasia at 5 years in individuals who have had screening colonoscopy. Methods: We studied 1193 participants aged 50-75 to identify factors associated with interval advanced neoplasia during a 5-year follow-up period. Participants underwent screening and 5-year colonoscopy from 1994-1997 at 13 Veterans Affairs Medical Centers. Advanced neoplasia included an adenoma ≥ 1cm, villous histology, high-grade dysplasia, or carcinoma. Risk factors were self-reported at baseline. We performed a multivariable logistic regression analysis of risk for interval advanced neoplasia, adjusting for age, smoking, alcohol use, BMI, colon cancer in first degree relatives, diabetes, cardiovascular disease, and prior outcome. Results: Participants were mostly male (97%) and white (83%). At 5 years, 392 participants (33%) had small adenomas < 1cm, and 92 participants (7.7%) had advanced neoplasia. In multivariable analyses, risk for interval advanced neoplasia was associated with age in 10-year increments (OR, 2.09; 95% CI, 1.39-3.13), diabetes (OR, 1.95; 95% CI, 1.12-3.41), prior small adenomas (OR, 4.02; 95% CI, 1.65-9.80), and prior advanced neoplasia (OR, 12.41; 95% CI, 5.08-30.30). Conclusions: In this prospective screening study, we identified diabetes as an independent risk factor for interval advanced neoplasia. Future guidelines should consider enhanced follow up of diabetic patients.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2023 ASCO Gastrointestinal Cancers Symposium
First Author: Shai Friedland
2024 ASCO Gastrointestinal Cancers Symposium
First Author: Derek W. Ebner
2023 ASCO Annual Meeting
First Author: Fang Gu
2024 ASCO Gastrointestinal Cancers Symposium
First Author: Brendan Chia